Fortress Biotech 2025 revenue rises, net loss narrows

Fortress Biotech

31/03/2026 21:18

Corrects revenue to $63.3 mln, from $61.2 mln, in Key Details table

Overview

U.S. biopharma firm's 2025 revenue rose yr/yr, with net loss narrowing sharply

Outlook

Fortress expects to receive at least $100 mln from Cyprium via future dividends and agreements

Company remains eligible for up to $4.8 mln CVR and 2.5% royalty on UNLOXCYT sales

Fortress could receive up to $128 mln in sales milestones and tiered royalties from ZYCUBO

Result Drivers

DERMATOLOGY PRODUCT SALES - Increased revenue from commercial launch and sales of Emrosi by Journey Medical

Company press release: ID:nGNX6ZZX4h

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
$63.3 mln
$73.34 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Fortress Biotech Inc is $10.75, about 298.1% above its March 30 closing price of $2.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)